At the European Cancer Congress (ECC) 2015, John Crown, MD, MBA, of St Vincents University Hospital, Dublin, Ireland, discusses the low-risk registry results from Trial Assigning IndividuaLized Options for Treatment (TAILORx). TAILORx is a prospective phase 3 clinical trial designed to evaluate the role of endocrine therapy and chemoendocrine therapy in patients with oestrogen receptor (ER)-positive, HER2-negative, node-negative breast cancer whose treatment was guided by the Oncotype DXรยฎ Breast Cancer Assay Recurrence Scoreรยฎ results. The results showed that adding genomic information provided by the Oncotype DXรยฎ Breast Cancer Assay may influence the selection of patients for adjuvant chemotherapy based on standard clinicopathological criteria.
This content is supported by Genomic Health, Inc.
European Medical Journal
Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews